Newsroom
Follow us as we passionately pursue our goal of improving life for those with cancer.
Get the latest
-
AVEO Pharmaceuticals, Inc. to Present at Upcoming Oncology Medical Meetings and Investment Conference
Download PDF CAMBRIDGE, Mass., Sep 28, 2010 (BUSINESS WIRE) — AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that the company will have a presence at two upcoming oncology medical meetings and Citi’s 5th Annual Biotech Day investment conference. Data from AVEO’s tivozanib clinical development program
-
AVEO Pharmaceuticals, Inc. Appoints Michael P. Bailey to the Newly Created Position of Chief Commercial Officer
Download PDF Company Enhances Leadership Team and Prepares for Forward Integration CAMBRIDGE, Mass., Sep 13, 2010 (BUSINESS WIRE) — AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced the appointment of Michael P. Bailey to the newly created role of chief commercial officer, as well as
-
AVEO Pharmaceuticals, Inc. to Present at Several Upcoming Investment Conferences
Download PDF CAMBRIDGE, Mass., Sep 02, 2010 (BUSINESS WIRE) — AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that the company’s management will present at several upcoming investment conferences. Tuan Ha-Ngoc, president and chief executive officer, is scheduled to present at the following events: David
-
AVEO Achieves Enrollment Target Ahead of Schedule for Pivotal Phase 3 Trial of Tivozanib in Patients with Advanced Renal Cell Carcinoma
Download PDF CAMBRIDGE, Mass. Aug 12, 2010 — (BUSINESS WIRE) — AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that it has achieved its enrollment target for TIVO-1, its global Phase 3 clinical trial for its oral, triple VEGF receptor inhibitor, tivozanib, in patients with
-
AVEO Pharmaceuticals, Inc. to Present at the Canaccord Genuity 30th Annual Global Growth Conference
Download PDF CAMBRIDGE, Mass., Aug 05, 2010 (BUSINESS WIRE) — AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that Tuan Ha-Ngoc, president and chief executive officer, is scheduled to present at the Canaccord Genuity 30th Annual Global Growth Conference on Thursday, August 12, 2010 at 8:30
-
AVEO Pharmaceuticals to Present at Cancer Stem Cells & The Tumor Microenvironment Conference
Download PDF AVEO’s Patented Tivozanib Biomarker Highlighted as Part of IBC’s Drug Discovery & Development Week CAMBRIDGE, Mass., Aug 02, 2010 (BUSINESS WIRE) — AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that Murray Robinson, Ph.D., senior vice president, translational medicine, is scheduled to present
-
AVEO Reports Second Quarter 2010 Accomplishments and Financial Results
Download PDF Advancement of Innovative Pipeline; Achievement of Collaboration-Driven Milestone CAMBRIDGE, Mass., Jul 29, 2010 (BUSINESS WIRE) — AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today provided an update on recent research and development (R&D) and business accomplishments, and announced financial results for the quarter ended
-
AVEO Pharmaceuticals, Inc. Announces Timing for Second Quarter 2010 Financial Results, Webcast and Conference Call
Download PDF CAMBRIDGE, Mass., Jul 22, 2010 (BUSINESS WIRE) — AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that financial results for the company’s second quarter ended June 30, 2010 will be released before the market opens on Thursday, July 29, 2010. The AVEO management
Follow us on social media
Media inquiries
For media inquiries, please contact:
John F. Kouten, CEO
JFK Communications, Inc.
jfkouten@jfkhealth.com
Direct: 609-241-7352
Download our media kit:
Meet our leadership team
The AVEO oncology management team comprises executives with years of oncology and pharmaceutical industry experience and expertise with a proven track record for success in bringing important new therapies to patients.